Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure
Open Access
- 25 May 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 31 (14) , 1752-1763
Abstract
Elevated brain natriuretic peptide (BNP) and tumour marker antigen carbohydrate 125 (CA125) levels have shown to be associated with higher risk for adverse outcomes in patients with acute heart failure (AHF). Nevertheless, no attempt has been made to explore the utility of combining these two biomarkers. We sought to assess whether CA125 adds prognostic value to BNP in predicting 6-month all-cause mortality in patients with AHF. We analysed 1111 consecutive patients admitted for AHF. Antigen carbohydrate 125 (U/mL) and BNP (pg/mL) were measured at a median of 72 ± 12 h after instauration of treatment. Antigen carbohydrate 125 and BNP were dichotomized based on proposed prognostic cutpoints, and a variable with four categories was formed (BNP–CA125): C1 = BNP < 350 and CA125 < 60 (n = 394); C2 = BNP ≥ 350 and CA125 < 60 (n = 165); C3 = BNP < 350 and CA125 ≥ 60 (n = 331); and C4 = BNP ≥ 350 and CA125 ≥ 60 (n = 221). The independent association between BNP–CA125 and mortality was assessed with the Cox regression analysis, and their added predictive ability tested by the integrated discrimination improvement (IDI) index. At 6 months, 181 deaths (16.3%) were identified. The cumulative rate of mortality was lower for patients in C1 (7.8%), intermediate for C2 and C3 (17.8% and 16.9%, respectively), and higher for C4 (37.2%), and P-value for trend P < 0.001) and intermediate when only one of them was elevated: (C2 vs. C1: HR = 1.71, 95% CI = 1.00–2.93; P = 0.050) and (C3 vs. C1: HR = 2.10, 95% CI = 1.30–3.39; P = 0.002). Moreover, when CA125 was added to the clinical model + BNP, a 10.4% (P < 0.0001) improvement in the IDI (on the relative scale) was found. In patients admitted with AHF, CA125 added prognostic value beyond the information provided by BNP, and thus, their combination enables better 6-month risk stratification.Keywords
This publication has 31 references indexed in Scilit:
- Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart FailureJACC, 2008
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Value of BNP and tumour marker CA125 in patients with heart failureActa Cardiologica, 2008
- Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failureAmerican Heart Journal, 2008
- Selection of important variables and determination of functional form for continuous predictors in multivariable model buildingStatistics in Medicine, 2007
- Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure?Heart, 2006
- The Seattle Heart Failure ModelCirculation, 2006
- Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening MarkerAmerican Journal of Epidemiology, 2004
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Usefulness of serum CA125 measurement for monitoring pericardial effusion.Japanese Circulation Journal, 1993